SEC Tracker
Get the app

Omeros OMER

Omeros: signs a material agreement, ends a material agreement and 2 other items

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
  • Signs a material agreement (1.01)
  • Ends a material agreement (1.02)
  • Takes on a new financial obligation (2.03)
  • Sells unregistered shares (3.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025
  5. Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025